Fig. 5: MYD88 S257D rescues cell growth in MYD88 L265P addicted cell lines. | Blood Cancer Journal

Fig. 5: MYD88 S257D rescues cell growth in MYD88 L265P addicted cell lines.

From: The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain

Fig. 5

A Immunoblot analysis of MYD88 in OCI-LY10 and TMD8 treated for 3 days with 500 ng/ml doxycyline. β-actin was used as loading control. B Immunoblot analysis for MYD88 in OCI-LY10 and TMD8 transduced with different MYD88 mutants. Cells were transduced with an empty vector (EV) or an expression vector for MYD88 (WT, S257D, S257A or L265P) and sorted for GFP expression. β-actin was used as loading control. C Flow cytometric analysis in OCI-LY10 and TMD8 of the number of viable cells, as determined by 7-AAD staining, after 5 days of treatment with 500 ng/ml doxycycline in cell lines transduced with inducible shRNA constructs targeting MYD88. The number of viable cells was normalized to the vehicle-treated condition. Data are presented as mean ± SD of three independent experiments. **P < 0.01 using 2-way ANOVA with Bonferroni’s multiple comparisons test. D Flow cytometric analysis of the number of viable cells after 5 days of treatment with 500 ng/ml doxycycline in cell lines OCI-LY10 or TMD8 transduced with an inducible shRNA construct targeting MYD88 3’UTR in combination with an empty vector (EV) or an expression vector for MYD88 (WT, S257D, S257A or L265P). The number of viable cells was normalized to the vehicle-treated condition. Data are presented as mean ± SD of four independent experiments. **P < 0.01 using 2-way ANOVA with Bonferroni’s multiple comparisons test.

Back to article page